Zacks Research Has Pessimistic Outlook of IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at Zacks Research lowered their Q1 2026 earnings per share (EPS) estimates for Iovance Biotherapeutics in a research report issued on Tuesday, July 15th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of ($0.22) for the quarter, down from their prior forecast of ($0.21). The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics' Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.30) EPS.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.11). The company had revenue of $49.32 million during the quarter, compared to analyst estimates of $83.40 million. Iovance Biotherapeutics had a negative net margin of 176.49% and a negative return on equity of 49.71%. The company's quarterly revenue was up 6795.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.42) EPS.

IOVA has been the subject of several other reports. UBS Group downgraded shares of Iovance Biotherapeutics from a "buy" rating to a "neutral" rating and cut their target price for the company from $17.00 to $2.00 in a research note on Friday, May 16th. Chardan Capital dropped their price objective on Iovance Biotherapeutics from $30.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Citizens Jmp downgraded Iovance Biotherapeutics from an "outperform" rating to a "market perform" rating in a research note on Friday, May 9th. JMP Securities reissued a "market perform" rating on shares of Iovance Biotherapeutics in a report on Friday, May 9th. Finally, Mizuho cut their price target on Iovance Biotherapeutics from $30.00 to $10.00 and set an "outperform" rating for the company in a report on Monday, May 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $12.22.

Iovance Biotherapeutics Price Performance

IOVA stock traded up $0.09 during trading hours on Friday, reaching $2.43. The stock had a trading volume of 3,352,885 shares, compared to its average volume of 9,414,320. The stock has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $3.69. Iovance Biotherapeutics has a fifty-two week low of $1.64 and a fifty-two week high of $12.51. The stock has a market capitalization of $809.78 million, a PE ratio of -1.95 and a beta of 0.85.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its position in shares of Iovance Biotherapeutics by 7.4% in the fourth quarter. Northern Trust Corp now owns 2,414,807 shares of the biotechnology company's stock valued at $17,870,000 after acquiring an additional 166,231 shares during the period. Wells Fargo & Company MN raised its stake in Iovance Biotherapeutics by 0.8% in the 4th quarter. Wells Fargo & Company MN now owns 580,245 shares of the biotechnology company's stock worth $4,294,000 after purchasing an additional 4,401 shares in the last quarter. California State Teachers Retirement System boosted its holdings in Iovance Biotherapeutics by 7.3% in the 4th quarter. California State Teachers Retirement System now owns 203,241 shares of the biotechnology company's stock valued at $1,504,000 after purchasing an additional 13,774 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Iovance Biotherapeutics by 4.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,989,340 shares of the biotechnology company's stock worth $14,721,000 after purchasing an additional 76,196 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Iovance Biotherapeutics by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 27,534,340 shares of the biotechnology company's stock worth $203,754,000 after purchasing an additional 220,373 shares in the last quarter. Institutional investors own 77.03% of the company's stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.